A Multicenter, Open-Label, Phase I Study of AJ1-11095 Administered as Oral Monotherapy in Patients with Primary Myelofibrosis PMF, Post-Polycythemia Vera Myelofibrosis PPV-MF, or Post-Essential Thrombocythemia Myelofibrosis PET-MF Who Have Been Failed by a Type I JAK2 Inhibitor JAK2i

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT06343805

Study #:
STUDY00160874

Start Date:
Dec 03, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06343805

View Complete Trial Details & Eligibility at ClinicalTrials.gov